Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer

被引：1
|
作者：
Kotani, N. [1 ]
Katsumata, N. [1 ]
Yonemori, K. [1 ]
Hirakawa, A. [2 ]
Yamamoto, H. [1 ]
Ono, M. [1 ]
Hirata, T. [1 ]
Yunokawa, M. [1 ]
Kouno, T. [1 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Fujiwara, Y. [1 ]
机构：
[1] Natl Canc Ctr, Breast & Med Oncol Div, Tokyo, Japan
[2] Tokyo Univ Sci, Grad Sch Engn, Dept Management Sci, Tokyo 162, Japan
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 72卷
关键词：
D O I：
10.1016/S1040-8428(09)70099-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer:: A phase II study
    Mäenpää, JU
    Grénman, SE
    Jalkanen, JT
    Kuoppala, TA
    Leminen, AO
    Puistola, US
    Vuolo-Merilä, PM
    Yliskoski, MH
    GYNECOLOGIC ONCOLOGY, 2006, 101 (01) : 114 - 119
  • [42] Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients?
    Zola, P.
    Ferrero, A.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 213 - 214
  • [43] Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer
    Fountzilas, G
    Athanassiades, A
    Papadimitriou, V
    Dimopoulos, MA
    Bafaloukos, D
    Aravantinos, G
    Nicolaides, C
    Kalofonos, HR
    Papakostas, P
    Xiros, N
    Razi, E
    ONCOLOGY-NEW YORK, 1998, 12 (01): : 45 - 48
  • [44] Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer
    Zhang, Li
    Zhou, Qi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 837 : 64 - 71
  • [45] First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: A phase I study
    Sehouli, J
    Stengel, D
    Elling, D
    Ortmann, O
    Blohmer, J
    Riess, H
    Lichtenegger, W
    GYNECOLOGIC ONCOLOGY, 2002, 85 (02) : 321 - 326
  • [46] Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer -: a study by the AGO OVAR Germany
    Hilpert, F.
    du Bois, A.
    Greimel, E. R.
    Hedderich, J.
    Krause, G.
    Venhoff, L.
    Loibl, S.
    Pfisterer, J.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 282 - 287
  • [47] Carboplatin (C) followed by sequential weekly paclitaxel (T) and gemcitabine (G) as first-line treatment for ovarian cancer.
    Perren, T
    Gore, M
    Hall, G
    Everard, M
    A'Hern, R
    Cole, C
    Gibbens, I
    Jenkins, A
    Kaye, S
    BRITISH JOURNAL OF CANCER, 2003, 88 : S58 - S58
  • [48] A phase II study of carboplatin and doxorubicin as the first-line treatment of ovarian cancer
    Tjuiandin, S.
    Chitia, L.
    Tryakin, A.
    Stenina, M.
    Panichenko, I.
    Zhordania, K.
    Garin, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 130 - 130
  • [49] Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
    Blank, Stephanie V.
    Christos, Paul
    Curtin, John P.
    Goldman, Noah
    Runowicz, Carolyn D.
    Sparano, Joseph A.
    Liebes, Leonard
    Chen, Helen X.
    Muggia, Franco M.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (03) : 451 - 456
  • [50] Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.
    Prithviraj, Gopi Kesaria
    Baksh, Kathryn Anissa
    Fulp, William J.
    Meredith, Ken
    Hoffe, Sarah E.
    Shridhar, Ravi
    Almhanna, Khaldoun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345